Thomas Martin, MD
Associate Editor
Dr. Martin is Clinical Research Director of Hematologic Malignancies at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center.
Articles by Thomas Martin, MD
Thomas Martin, MD, reflects on what's in store for 2024—including the SOHO Annual Meeting, myeloma advancements, and more.
The Blood Cancers Today Editorial Board offers their thoughts on the past year.
The panel gives their opinions on vaccine strategies for patients with myeloma receiving bispecifics.
The panel discusses optimal dosing for teclistamab.
Dr. Martin asks Dr. Chari to provide insights on adverse event management with talquetamab.
The panel continues the conversation around toxicity management for bispecific agents.
The panel addresses side effects that are commonly seen in patients receiving bispecifics.
The panel discusses their personal experience with bispecifics-related REMS programs.
The panel discusses where they think bispecifics have "the best role" in the myeloma treatment paradigm.
The panel provided insights on how they determine whether to give a patient with myeloma CAR T-cell therapy or a bispecific.
The panel discussed the FDA-approved bispecific agents for myeloma and how the options performed in clinical trials.
The Blood Cancers Today Editorial Board reflects on the latest news in the field so far in 2023.
Dr. Martin discusses key updates in multiple myeloma from ASCO, EHA, and the IMWG meetings.
The panel advises on patient hand off to local care teams following CAR T-cell therapy for myeloma.
The panel discusses side effect management with CAR T-cell therapy.
The panel addresses the choice between treating multiple myeloma with a bispecific agent or CAR T-cell therapy.
Drs. Martin and Voorhees discuss patient characteristics and populations that are suited for CAR-T therapy in myeloma.
The panel addresses the potential for frontline CAR-T use.
The panel debates whether CAR-T can be moved earlier in the course of myeloma treatment.
The panel discusses allogeneic CAR T-cell therapy and how it stacks up against autologous options.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.